Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?
about
Digitoxin medication and cancer; case control and internal dose-response studiesCancer, inflammation and the AT1 and AT2 receptorsRenin-angiotensin system blockade: Its contribution and controversyReview article: the pathophysiological roles of the renin-angiotensin system in the gastrointestinal tractAntihypertensive medication use and incident breast cancer in women.Repurposing of approved cardiovascular drugsCaV channels and cancer: canonical functions indicate benefits of repurposed drugs as cancer therapeuticsRole and therapeutic potential of G-protein coupled receptors in breast cancer progression and metastasesCombination antiangiogenesis therapy with marimastat, captopril and fragmin in patients with advanced cancerFamiliar drugs may prevent cancerAT1 receptor is present in glioma cells; its blockage reduces the growth of rat gliomaRenin-angiotensin system blockade for the risk of cancer and death.Interstitial fluid flow in cancer: implications for disease progression and treatment.Upregulation of angiotensin-converting enzyme by vascular endothelial growth factor.Association of angiotensin-converting enzyme inhibitor therapy and comorbidity in diabetes: results from the Vermont diabetes information systemA multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2.Angiotensin II type 2 receptor signaling significantly attenuates growth of murine pancreatic carcinoma grafts in syngeneic mice.Changes in the renin angiotensin system during the development of colorectal cancer liver metastases.Practical considerations of the pharmacology of angiotensin receptor blockers.Is cancer related to hypertension or to its treatment?Expression of Cathepsins B, D, and G in Isocitrate Dehydrogenase-Wildtype Glioblastoma.Use of angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers and cancer risk: a meta-analysis of observational studies.Genetic Association Study of Angiotensin II Receptor Types 1 (A168G) and 2 (T1247G and A5235G) Polymorphisms in Breast Carcinoma among Brazilian Women.miR-802 regulates human angiotensin II type 1 receptor expression in intestinal epithelial C2BBe1 cells.A critique of hypertension treatment trials and of their evaluation.Angiotensin-2 receptors (AT1-R and AT2-R), new prognostic factors for renal clear-cell carcinoma?Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine.Association between angiotensin I-converting enzyme gene polymorphism and susceptibility to cancer: a meta analysisSenescence-associated phenotypes in Akita diabetic mice are enhanced by absence of bradykinin B2 receptors.Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors.Clinical trials and tribulations.Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohortAngiotensin II directly induces muscle protein catabolism through the ubiquitin-proteasome proteolytic pathway and may play a role in cancer cachexiaAngiotensin-converting enzyme inhibitors/angiotensin receptor blockers therapy and colorectal cancer: a systematic review and meta-analysis.Prognonstic impact of renin-angiotensin system blockade in localised upper-tract urothelial carcinomaAssociations of the Insertion/Deletion Polymorphism in the ACE Gene and Risk of Gastric Cancer: A Meta-Analysis.Angiotensin-converting enzyme inhibitors side effects--physiologic and non-physiologic considerations.Angiotensin peptides and lung cancer.The gene polymorphism of the angiotensin I-converting enzyme correlates with tumor size and patient survival in colorectal cancer patients.Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma.
P2860
Q21261338-878CA0FD-B2FB-4F5C-8FF5-877E46953C3BQ24806378-D77AFC08-E92F-4C90-8822-CEED90444DD0Q26827221-196C5619-DD9A-4B26-AB2A-F3E77672D880Q27009109-AD4432DE-8DC5-49AD-9193-AA51867E6BFBQ27317184-0574EBCD-AAAD-41D4-B4C9-7AE067C5CC4AQ28074453-1977D529-4178-48D5-A322-6BC345B4AD4AQ28078594-8674357A-2D05-4FA1-A259-F523BC4C66D0Q28084420-D2F3CC3F-9AC6-4591-8AE1-252997AE0066Q28168748-C5551D58-13E3-4F85-B260-D3DC4D017E40Q28186835-3ABE1614-D86A-4CB3-B3E1-7B123A02B74BQ28365043-82348169-DEBE-4A81-A0A2-43702B43F9F8Q30249043-A5647A8A-2761-4608-BA58-645CB174ECFFQ30411142-F5B6A57D-06E9-4665-B94E-AA5309CE61F0Q31833925-22750DCA-5603-4497-BB30-5ACADFC79AC6Q33390497-E0B75043-5584-43F0-A1C9-F2309640F43FQ33407858-E7DA5E7E-833A-4161-B44D-81D0EA244AF9Q33534042-24A952E8-0CFB-4D6A-89A6-29EDAE222AB9Q33551485-A791DFC3-E59D-4515-9672-BF360E88EA48Q33650699-0EBAAD73-1D7B-44EB-B8B2-026811559ADDQ33697736-8E80E044-280E-4585-A226-27EF93268CB5Q33734645-B889486F-16AE-4578-B4E1-3C22AD255CB0Q34005101-5097323F-69C2-4B98-A408-C635284F1D31Q34042721-51885ABB-3CBA-48C8-A63C-DD172FDE80C5Q34121433-016D72C8-72E1-4582-AC7B-43765D570B98Q34328239-DE17938D-71EB-4E91-8B3D-EE4C4971C707Q34363440-24D664ED-86F3-4848-9C8B-27CA4024D9F3Q34363486-05EE9D29-BDA5-4624-8ABE-7D5C71440B5EQ34371778-557FC02F-4194-4FF5-8AB5-B8605929B180Q34520210-6540D808-D70B-4E80-8C85-5DF5605BB10AQ34582878-EE82F3C3-23C4-4174-A33F-BD56270BABDCQ34941150-4D5022ED-161F-44F7-A914-BED56BABA8DCQ35131970-0BC3B3ED-5A65-44BB-95E0-E0362C6FC627Q35552890-7DBAED33-9D0B-4153-AB19-5149A14CCF26Q35665360-77EDCFEB-A42B-4C49-9C6F-FA59BD24D996Q35681985-54D6BC5A-F740-4DFE-9402-30060F77C02FQ35755375-A1F166AE-0B38-4AFB-9D5E-C464E91A065DQ35834193-670B21BF-D26D-4918-9CAA-3DDE8BECC854Q35857462-0DC49F39-E187-4480-8D8F-DF6B1F41F221Q36012552-3BAD5E87-2D59-48BF-AB6B-A63554565305Q36051199-8A1BDE52-F0F7-48BA-B6B3-3645CDD04970
P2860
Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?
description
1998 nî lūn-bûn
@nan
1998 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?
@ast
Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?
@en
Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?
@nl
type
label
Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?
@ast
Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?
@en
Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?
@nl
prefLabel
Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?
@ast
Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?
@en
Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?
@nl
P2093
P1433
P1476
Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?
@en
P2093
C R Gillis
G T McInnes
I R McCallum
J W Robertson
L S Murray
P A Meredith
P L MacKinnon
P304
P356
10.1016/S0140-6736(98)03228-0
P407
P577
1998-07-01T00:00:00Z